Navigation Links
Inability of Pixantrone to Form Toxic Iron Complexes Results in Significant Reduction in Cardiac Cell Toxicity Compared to Currently Marketed Anthracyclines
Date:12/8/2009

eristic of the drug to iron complex formation, confirming the expected 1:3 Fe(II)-drug ratio for both doxorubicin and mitoxantrone. In contrast, no spectrophotometric changes were observed with iron added to pixantrone, clearly demonstrating that pixantrone does not bind iron. In vitro studies using H2C9 rat myocardial cells indicate that pixantrone (ID50 >50 ug/ml) is far less toxic than doxorubicin (ID50= 1 ug/ml). Moreover, pixantrone does not induce significant reactive oxygen species (ROS) production in the H2C9 cells compared to doxorubicin.

About Pixantrone

Pixantrone (BBR 2778), is a novel topoisomerase II inhibitor with an aza-anthracenedione molecular structure that differentiates it from the anthracyclines and other related chemotherapy agents. Anthracyclines are the cornerstone therapeutic for the treatment of lymphoma, leukemia, and breast cancer. Although they are sufficiently effective to be used as first-line (initial) treatment, they cause cumulative heart damage that may result in congestive heart failure many years later. As a result, there is a lifetime limit of anthracycline doses and most patients who previously have been treated with an anthracycline are not able to receive further anthracycline treatment if their disease returns. It also can be administered through a peripheral vein rather than a central implanted catheter as required for other drugs in this class. Pixantrone has been granted fast track status designation.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.CellTherapeutics.com.

Sign up for email alerts and get RSS feeds at our Web site, '/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. BD Ranked in the Top 100 Greenest Big Companies by Newsweek; Named Again to Dow Jones Sustainability World and North America Indexes
2. US Oncology, Inc. to Exhibit iKnowMed(TM) at the 2009 ASCO EHR Symposium: Harnessing the EHR: From Incentives to Sustainability
3. 18 month Follow-up Data on Phase III Study of Pixantrone in Late Stage Relapsed or Refractory, Aggressive Non-Hodgkins Lymphoma Continues to Demonstrate Significant Improvement in Complete Remission and Progression Free Survival Over Standard Chemotherap
4. FDA Sets Action Date of April 23, 2010 for Review of Pixantrone NDA
5. Responses After Completion of Therapy Increase Pixantrone Complete Remission (CR)/Unconfirmed Complete Remission (CRu) Rate to 24% and Overall Response Rate (ORR) to 40% Compared to 7% and 14% for Comparator Agents in Phase III EXTEND Trial in 3rd Line Th
6. Overview of Pixantrone Phase III Clinical Data Presentation at American Society of Clinical Oncology 2009 Annual Meeting Now Available at Clinical Care Options
7. Pixantrone in Combination with Chemotherapy Regimens Produces Overall Response Rates of 58-74% with Complete Remission Rates of 37-57% in Relapsed/Refractory Aggressive or Indolent NHL
8. Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment
9. Pixantrone Phase 3 Data to be Presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting
10. Compared to Standard Therapies, Pixantrone Decreases Time to Achieve Complete Remission by 47% in Relapsed Aggressive Non-Hodgkins Lymphoma
11. Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... 2015 This report analyzes the worldwide markets for ... following Segments: Standard Intraocular Lenses, and Premium Intraocular Lenses. The ... Canada , Japan , ... Latin America , and Rest of World. Annual estimates ... Also, a seven-year historic analysis is provided for these markets. ...
(Date:5/28/2015)... , May 28, 2015 ... has announced the addition of the  "North ... And Forecasts (2014 - 2019)"  report to ... Ultrasound is a type of ... look at body parts and structures inside ...
(Date:5/28/2015)... May 28, 2015 KaloBios Pharmaceuticals, Inc. (Nasdaq: ... Ronald A. Martell , to the position of Executive ... the KaloBios Board of Directors. In this new role, ... team to refine and execute on the strategic plan ... developing therapeutics for orphan oncology indications with high unmet ...
Breaking Medicine Technology:World Intraocular Lenses Industry 2World Intraocular Lenses Industry 3World Intraocular Lenses Industry 4World Intraocular Lenses Industry 5World Intraocular Lenses Industry 6World Intraocular Lenses Industry 7World Intraocular Lenses Industry 8World Intraocular Lenses Industry 9World Intraocular Lenses Industry 10World Intraocular Lenses Industry 11World Intraocular Lenses Industry 12World Intraocular Lenses Industry 13World Intraocular Lenses Industry 14World Intraocular Lenses Industry 15World Intraocular Lenses Industry 16World Intraocular Lenses Industry 17World Intraocular Lenses Industry 18World Intraocular Lenses Industry 19World Intraocular Lenses Industry 20World Intraocular Lenses Industry 21World Intraocular Lenses Industry 22World Intraocular Lenses Industry 23World Intraocular Lenses Industry 24World Intraocular Lenses Industry 25World Intraocular Lenses Industry 26North America Ultrasound Devices Market Report 2014-2019 - Technology and Applications 2KaloBios Appoints Ronald A. Martell Executive Chairman 2KaloBios Appoints Ronald A. Martell Executive Chairman 3KaloBios Appoints Ronald A. Martell Executive Chairman 4KaloBios Appoints Ronald A. Martell Executive Chairman 5
... Adeona Pharmaceuticals, Inc. (AMEX: AEN ), a ... diseases, announced today that it will hold a conference ... study evaluating reaZin for the dietary management ... April 15, 2011, at 8:00 a.m. (HAST)/2:00 p.m. (EDT). ...
... BATESVILLE, Ind., April 14, 2011 Hill-Rom (NYSE: ... on Tuesday, May 24, 2011 in New York City.  John ... executives will host investors and analysts to discuss the company,s ... webcast the entire conference beginning at 9 a.m. EDT on ...
Cached Medicine Technology:Adeona to Host Conference Call 2
(Date:5/29/2015)... Javlin continues to fulfill its worldwide ... a larger team, with the intention to better serve ... in the U.S. and Canada. , Javlin Inc., the ... growth in 2014 with its strongest earnings to date, ... platform, CloverETL. To accelerate further progress and ensure exceptional ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 The annual aesthetic ... Surgery (ASAPS), was held in Montreal from May 14-19th. ... for aesthetic professionals from around the world; dedicating itself exclusively ... the many renowned plastic surgeons to attend this ... the six-day event, Dr. Vitenas was given the honor of ...
(Date:5/29/2015)... Healthpointe is excited to announce that they are now ... in Orange County. The Supartz Therapy is a cost-effective, ... for patients with osteoarthritis, and will be administered by ... of Healthpointe. Supartz is an injection of made from ... a natural substance found in joint cartilage. Also known ...
(Date:5/29/2015)... Metamora, Michigan (PRWEB) May 29, 2015 ... region and can cause significant physical, sexual, and psychological ... life altering disorder of Vulvodynia. The actual diagnosis is ... Excellence in Endometriosis, they realize that this problem can ... is experiencing any of these symptoms, they need to ...
(Date:5/29/2015)... The popular all-natural supplement brand, Liporidex, ... Select Program that gives bonuses to members for their ... 100 members per year, lucky members who are selected ... fitness experts at Nuretix Research, and get exclusive benefits ... they attain and maintain their weight loss and fitness ...
Breaking Medicine News(10 mins):Health News:Growth of Data Integration Platform CloverETL Continues in North America 2Health News:Dr. Paul Vitenas Presents at 2015 Aesthetic Meeting 2Health News:Dr. Paul Vitenas Presents at 2015 Aesthetic Meeting 3Health News:Healthpointe is Now Offering Supartz Joint Fluid Therapy at their Anaheim Clinic and La Mirada Clinic. 2Health News:Liporidex, a Sports Nutrition Supplement Brand, Is Searching For Members For Their Exclusive L-Style Select Program Which Rewards Members For Their Achievements 2
... comes a new study that links breakdown of myelin ... of California, Los Angeles (UCLA) researchers showed that genetic ... breakdown, may prove useful in assessing treatments for prevention ... a process uniquely built up in humans, arguably is ...
... The New Women's Health Initiative (WHI) suggests, a prolonged ... carbohydrates results in negligible weight gain. // ... postmenopausal women Vis a Vis variations in consumed foods ... advised to reduce the fat consumption to 20% of ...
... body cavity rather than the conventional intravenous route, seems to ... cancer patients, according to a latest study. // ... among American women. In line with the above finding, the ... all ovarian cancer patients. ,This new treatment modality ...
... help in slowing down the progress of Alzheimer's disease, ... and Chile. The healthy brain // ... their study, to be published in the American Chemical ... surgery, has the potential to destroy beta-amyloid fibrils and ...
... Rotateq and Rotarix in more than 1, 30, 000 ... The vaccines have been found to be 98% and ... 1/3rd of all hospital infections worldwide. ,A ... 1990’s. This however, was withdrawn from the market owing ...
... A leaflet claiming that traditional Chinese medicine was safer ... code in the UK, an industry watchdog said on ... essential treatment from qualified doctors for serious medical conditions, ... produced by Ever Well Ltd, also claimed that serious ...
Cached Medicine News:Health News:Death Risk Of Ovarian Cancer Reduced By Intraperitoneal Chemotherapy 2Health News:Diarrhea Vaccine Trials Promises Prevention of Rotavirus Infection 2Health News:Chinese medicine leaflet broke advertising code 2
Each handle is designed to fit a specific trephine size....
Each handle is designed to fit a specific trephine size....
Each handle is designed to fit a specific trephine size....
Each handle is designed to fit a specific trephine size....
Medicine Products: